IRIX - IRIDEX GAAP EPS of -$0.14 revenue of $13.8M lowers FY22 revenue guidance

• IRIDEX press release ( NASDAQ: IRIX ): Q2 GAAP EPS of -$0.14.
• Revenue of $13.8M (+3.0% Y/Y).
• Cyclo G6 product family revenue of $3.5 million, a decrease of 3% year-over-year
  • 15,000 Cyclo G6 probes sold, a 6% decrease year-over-year and a 2% increase quarter-over-quarter
  • 48 Cyclo G6 Glaucoma Laser Systems sold, compared to 47 in the prior year quarter
• Iridex now expects total revenue for fiscal year 2022 to range from $56 million to $58 million ($58.19M consensus), reflecting growth of 4% to 8% over fiscal year 2021. This compares to the previous range of $57 million to $59 million.
• Cyclo G6 probe sales are now expected to range from 61,000 to 63,000, representing 5% to 8% growth. This compares to the previous range of 67,000 to 70,000.
• The Company continues to expect Glaucoma Laser System installed base to expand by 225 to 250 in 2022.

For further details see: